The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
| | |
PRELIMINARY PROSPECTUS | | SUBJECT TO COMPLETION, DATED APRIL 28, 2022 |
$110,000,000
Atlas Growth Acquisition Limited
11,000,000 Units
Atlas Growth Acquisition Limited is a blank check company incorporated as a Cayman Islands exempted company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we currently intend to focus our efforts in Asia (excluding China) with an emphasis on sourcing opportunities that are in the healthcare, consumer technology and technology, media and telecommunications industries. We will not undertake an initial business combination with any entity that is based or located in or that conducts its principal business operations in China (including Hong Kong and Macau). We do not have any specific business combination under consideration and we have not (nor has anyone on our behalf), directly or indirectly, contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to such a transaction with our company.
This is an initial public offering of our securities. We are offering 11,000,000 units at an offering price of $10.00 per unit. Each unit consists of one Class A ordinary share, one redeemable warrant, which we refer to throughout this prospectus as the “public warrants” and one right to receive one-tenth (1/10) of a Class A ordinary share. Each warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per full share, subject to adjustment as described in this prospectus. Each warrant will become exercisable 30 days after the completion of an initial business combination, and will expire on the fifth anniversary of our completion of an initial business combination, or earlier upon redemption or liquidation. We will not issue fractional shares in connection with the exchange of rights. As a result, you must hold rights in multiples of ten in order to receive shares for all of your rights.
We have also granted the underwriters, a 45-day option to purchase up to an additional 1,650,000 units (over and above the 11,000,000 units referred to above) solely to cover over-allotments, if any.
We will provide our public shareholders with the opportunity to redeem their Class A ordinary shares upon the consummation of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account described below, including interest (net of taxes payable), divided by the number of then issued and outstanding Class A ordinary shares that were sold as part of the units in this offering, which we refer to as our “public shares.”
We have 15 months from the closing of this offering to consummate our initial business combination. However, if we anticipate that we may not be able to consummate our initial business combination within 15 months, we may, but are not obligated to, extend the period of time to consummate a business combination two times by an additional three months each time (for a total of up to 21 months to complete a business combination) as described in this prospectus. If we are unable to consummate our initial business combination within the above time period, we will distribute the aggregate amount then on deposit in the trust account, net of taxes payable, and less up to $50,000 of interest to pay liquidation expenses, pro rata to our public shareholders by way of the redemption of their shares and to cease all operations except for the purposes of winding up of our affairs, as further described herein. In such event, the warrants and rights will expire and be worthless.
We have issued to our sponsor, Atlas Growth Holdings Limited, and certain of its affiliates (collectively, our “initial shareholders”) an aggregate of 3,162,500 Class B ordinary shares (including up to an aggregate of 412,500 Class B ordinary shares subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part) in exchange for a capital contribution of $25,000, or approximately $0.008 per share. The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination on a one-for-one basis, subject to the adjustments described herein. The holders of our Class B ordinary shares will have the right to elect all of our directors prior to our initial business combination and the holders of our Class A ordinary shares will not be entitled to vote on the election of directors during such time.
In addition, our sponsor has committed to purchase from us an aggregate of 5,850,000 warrants (or 6,427,500 warrants if the over-allotment option is exercised in full) (the “private warrants”) at a price of $1.00 per warrant in a private placement for an aggregate purchase price of $5,850,000 (or $6,427,500 if the over-allotment option is exercised in full). Each private warrant will be identical to the warrants included in the units sold in this offering, except as described in this prospectus. The private warrants will be sold in a private placement that will close simultaneously with the closing of this offering, including the over-allotment option, as applicable.
There is presently no public market for our units, Class A ordinary shares, warrants or rights. We have applied to have our units listed on the Nasdaq Global Market, or Nasdaq, under the symbol “ATLAU” on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq. Once the securities comprising the units begin separate trading as described in this prospectus, we expect the Class A ordinary shares, warrants and rights will be traded on Nasdaq under the symbols “ATLA,” “ATLAW,” and “ATLAR” respectively. We cannot assure you that our securities will be approved for listing and, if approved, will continue to be listed on Nasdaq after this offering.
Our executive offices are currently located in Singapore. In addition, all of our executive officers and directors are located outside of the United States. As a result, it may be difficult for investors to effect service of process within the United States on our company, executive officers and directors, or enforce judgments obtained in the United States courts against our company, executive officers and directors, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States.
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and will therefore be subject to reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 28 for a discussion of information that should be considered in connection with an investment in our securities.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
No offer or invitation to subscribe for securities may be made to the public in the Cayman Islands.
| | | | | | | | | | | | |
| | Price to Public | | | Underwriting Discounts and Commissions(1) | | | Proceeds, Before Expenses, to us | |
Per Unit | | $ | 10.00 | | | $ | 0.55 | (2) | | $ | 9.45 | |
Total | | $ | 110,000,000 | | | $ | 6,050,000 | | | $ | 103,950,000 | |
(1) | The table does not include certain other fees and expenses payable to the underwriters in connection with this offering, including 7,500 founder shares which will be transferred by the sponsor to an affiliate of Brookline Capital markets, one of the joint book-running managers. Please see the section titled “Underwriting” for further information relating to the underwriting arrangements agreed to between us and the underwriters in this offering. |
(2) | Includes $3,850,000, or $0.35 per unit, equal to 3.5% of the gross proceeds of this offering (or $4,427,500 if the underwriters’ over-allotment option is exercised in full) payable to the underwriters as deferred underwriting discounts and commissions from the funds to be placed in the trust account described below. Such funds will be released to the underwriters only upon consummation of an initial business combination, as described in this prospectus. If the business combination is not consummated, such deferred discount will be forfeited. |